Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasirox
Deferasiroxum
Brand Names
Deferasorox
Auro-deferasirox (type J)
Apo-deferasirox (type J)
Deferasirox Mylan
Sandoz Deferasirox (type J)
Taro-deferasirox (type J)
Taro-deferasirox
Deferasirox Oral Granules
Deferasirox
PMS-deferasirox (type J)
Jadenu
PMS-deferasirox
Sandoz Deferasirox
Deferasirox Accord
Teva-deferasirox (type J)
Apo-deferasirox
Deferasirox oral
Exjade
Deferasirox (type J)
Teva-deferasirox
Jamp Deferasirox (type J)
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682